The initial success of Sildenafil undeniably transformed the drug landscape, but betting in companies strongly reliant on off-patent versions presents a challenging picture. While early profits were impressive, the cessation of patents and the appearance of cheaper alternatives have diminished sales. Thus, a thorough assessment of present revenue s